Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

114.37 +1.01 (+0.89%)
Streaming Delayed Price Updated: 12:50 PM EDT, Oct 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Global Sports Nutrition Market Projected to Reach $78 Billion as Muscle Repair & Growth Becoming Vitally Important
From FN Media Group LLC
Via GlobeNewswire
Jim Cramer Calls This Healthcare Stock A 'Worthy Spec,' Recommends Avoiding Canada Goose
Cramer recommends staying away from Canada Goose, even though it reported better-than-expected Q4 earnings. 
Via Benzinga
These Dividend Stocks Are an Investor's Best Friend
These two healthcare stocks are well-known for their top-tier dividend programs. 
Via The Motley Fool
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
How Is The Market Feeling About Abbott Laboratories?
Via Benzinga
3 S&P 500 Stocks That Have Proven Themselves Recession-Proof
Corrections are a part of investing and investors would be smart to have these three S&P 500 stocks to buy when the inevitable happens. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Best Foundational Stocks
Building the foundation of investors portfolio with the best US foundational stocks by sector. 
Via Talk Markets
Catalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year. 
Via Investor's Business Daily
Amazon, Abbott Laboratories And 2 Other Stocks Insiders Are Selling
Via Benzinga
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Check out these healthcare stocks for some healthy payouts. 
Via The Motley Fool
What the Options Market Tells Us About Abbott Laboratories
Via Benzinga
Behind the Scenes of Abbott Laboratories's Latest Options Trends
Via Benzinga
Stock Market Crash Alert: 3 Must-Buy Healthcare Stocks When Prices Plunge
Investors should look for opportunities to buy these leading healthcare companies, each of which posted strong Q1 results. 
Via InvestorPlace
Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX
Via AB Newswire
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook. 
Via MarketBeat
7 Defensive Stocks Built to Withstand the Market’s Worst Storms
With the market operating under a worrisome backdrop, investors may want to target certain defensive stocks to buy. 
Via InvestorPlace
2 Beaten-Down Dividend Stocks to Buy and Hold Forever
These companies aren't in danger of becoming has-beens. 
Via The Motley Fool
Better Dividend Stock: AbbVie or Johnson & Johnson?
One thing is for sure: Dividend seekers can't go wrong with either. 
Via The Motley Fool
3 Dividend Stocks to Buy and Hold for the Next Decade
You'll get dividends and more with these great stocks. 
Via The Motley Fool
Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth
Intelligent Bio Solutions (Nasdaq: INBS) is a medical technology company developing and commercializing innovative, intelligent, rapid, noninvasive testing solutions. 
Via Talk Markets
Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes
It's not just enough for a company to pay a dividend, investors should look for dividend growth stocks that can continue to pay. 
Via InvestorPlace
3 Dividend Kings Down 11% You’ll Regret Not Buying on the Dip
These dividend stocks have proved time and again why they're the cream of the crop and will rise to the top once more. 
Via InvestorPlace
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
The Nasdaq and S&P 500 tumbled below their 50-day lines. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Stocks Fall As Geopolitics, Economic Worries Spook Investors, Chipmakers Sell Off, Bitcoin Tumbles To $60,000: What's Driving Markets Wednesday?
A sentiment of risk aversion looms over the markets during Wednesday’s trading session, triggering midday losses across the board in stocks and cryptocurrencies and prompting a flight towards bonds, as... 
Via Benzinga
Topics Bonds
Exposures Debt Markets
Abbott Laboratories (ABT) Q1 2024 Earnings Call Transcript
ABT earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
ABT Stock Earnings: Abbott Laboratories Beats EPS, Beats Revenue for Q1 2024
ABT stock results show that Abbott Laboratories beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Abbott Laboratories Outlook is Healthy: Buy the Dip
Abbott Laboratories had a steady quarter, producing growth, better-than-expected earnings, and raising the guidance. Analysts see the stock moving higher. 
Via MarketBeat
Exposures COVID-19
Abbott Beats Q1 Expectations With $10 Billion In Sales, $0.98 EPS
Abbott has reported a strong start to the year with sales reaching $10.0 billion in Q1, driven by a 10.8 percent increase in organic sales growth. 
Via Talk Markets
Dow Surges 200 Points; Abbott Laboratories Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.55% to 38,006.47 while the NASDAQ... 
Via Benzinga
Topics Stocks
Exposures US Equities
Abbott Undercuts Its 200-Day Line And A Flat Base Despite Its 'Solid' Quarterly Report
Abbott Laboratories came in Wednesday with a "solid" first-quarter report that included a guidance raise, but shares fell. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.